51
Participants
Start Date
February 14, 2012
Primary Completion Date
March 21, 2016
Study Completion Date
March 21, 2016
Tavokinogene Telseplasmid (tavo)
Patients received intratumoral injection(s) of tavo.
OncoSec Medical System (OMS)
Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
St. Luke's University Health Network, Bethlehem
Lakeland Regional Cancer Center, Lakeland
University of Colorado Denver, Denver
John Wayne Cancer Institute, Santa Monica
UCSF Helen Diller Comprehensive Cancer Center, San Francisco
Seattle Cancer Care Alliance /University of Washington Cancer Consortium, Seattle
OncoSec Medical Incorporated
INDUSTRY